nafamostat has been researched along with Duodenal Obstruction in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Duodenal Obstruction: Hindrance of the passage of luminal contents in the DUODENUM. Duodenal obstruction can be partial or complete, and caused by intrinsic or extrinsic factors. Simple obstruction is associated with diminished or stopped flow of luminal contents. Strangulating obstruction is associated with impaired blood flow to the duodenum in addition to obstructed flow of luminal contents.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamauchi, J | 1 |
| Takeda, K | 1 |
| Shibuya, K | 1 |
| Sunamura, M | 1 |
| Matsuno, S | 1 |
1 other study available for nafamostat and Duodenal Obstruction
| Article | Year |
|---|---|
Continuous regional application of protease inhibitor in the treatment of acute pancreatitis. An experimental study using closed duodenal obstruction model in dogs.
Topics: Animals; Benzamidines; Disease Models, Animal; Dogs; Duodenal Obstruction; Guanidines; Infusions, In | 2001 |